Enteral Glutamine in Critical Illness
|Critical Illness Sepsis Respiratory Insufficiency||Drug: Glutamine||Phase 2 Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Randomized Clinical Trial Comparing Enteral Glutamine Supplementation to Standard of Care Enteral Feeding in Critical Illness|
- Mortality [ Time Frame: 28 days ]
- Length of ICU stay [ Time Frame: 28 days ]
- Number of Ventilator Days [ Time Frame: 28 days ]
- Number of days receiving antibiotics [ Time Frame: 28 days ]
- Change in APACHE Score [ Time Frame: 72 hours ]
- Change in Number of SIRS Criteria [ Time Frame: 72 hours ]
- Change in Capillary Leak as measured by blood volume analysis [ Time Frame: 72 hours ]
- Change in CRP [ Time Frame: 72 hours ]
- Correlation between capillary permeability and APACHE Score [ Time Frame: 72 hours ]
- Correlation between capillary permeability and Mortality [ Time Frame: 72 hours ]
|Study Start Date:||May 2006|
|Study Completion Date:||September 2007|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
Active Comparator: A
Will receive enteral glutamine
Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
No Intervention: B
No enteral glutamine given
Glutamine, a nonessential amino acid, is preferred fuel for rapidly proliferating cells in human body. Those cells include the enterocytes in small intestine, lymphocytes, macrophages, and fibroblasts. Glutamine also transports nitrogen between tissues and serves as a precursor to glutathione which is a potent antioxidant. A healthy human body contains abundant glutamine, either from diet or from skeletal muscle tissue that synthesizes it.
During critical illness the demand for glutamine is increased. Rapid depletion of glutamine stores in critically ill patients has been described and correlated to increased mortality. Glutamine depletion may be deleterious in critical illness because of adverse effects on the essential functions mentioned above. For example glutamine depletion may cause gut mucosal barrier function to deteriorate, leading to bacterial translocation and enhanced systemic inflammatory response with increased risk for multisystem organ failure. Clinical trials performed in a wide range of patients with serious illness, including cancer, trauma, burn, major surgery and critical illness, have demonstrated possible benefits of glutamine supplementation. Interpretation of the results of multiple studies is made difficult based on differences in glutamine dosing, route of administration, population studied, and endpoints used.
Blood volume analysis has been shown to be a good measure of capillary leak. The DAXOR blood volume analyzer kit was recently approved by the FDA for blood volume analyses and also has the capacity of measuring capillary permeability by looking at the slope of albumin transudation. It is a simpler way to measure capillary permeability than other methods described.
Reviewing the previous study results, glutamine supplementation in parental form and with higher dose in various patient populations has shown evidence of being beneficial. Studies of enteral glutamine therapy have also showed benefits, but results are less consistent possibly because of the heterogeneous study methodology described above. Moreover, most of the studies are carried out in burn patients and surgical patients; there were few studies in critical ill medical patients. Finally no study has specifically looked at the mechanism via which glutamine has conferred protection.
Comparison: Critically ill patients given enteral tube feeds compared to critically ill patients given enteral tube feeds with supplemental glutamine.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00318331
|United States, Delaware|
|Newark, Delaware, United States, 19713|
|Principal Investigator:||Michael DePietro, M.D.|